Evolus (NASDAQ:EOLS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Evolus (NASDAQ:EOLS) from a hold rating to a buy rating in a research note published on Saturday morning.

A number of other research firms have also weighed in on EOLS. Mizuho set a $15.00 target price on shares of Evolus in a report on Wednesday, February 4th. HC Wainwright decreased their price target on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a research report on Wednesday, December 24th. BTIG Research reiterated a “buy” rating and set a $13.00 price objective on shares of Evolus in a research report on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Evolus in a research note on Monday, December 22nd. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Trading Down 3.3%

NASDAQ:EOLS opened at $5.35 on Friday. The business’s 50-day moving average is $5.01 and its 200 day moving average is $6.20. Evolus has a 12 month low of $4.09 and a 12 month high of $13.66. The company has a market capitalization of $348.07 million, a P/E ratio of -6.60 and a beta of 1.02.

Evolus (NASDAQ:EOLS) last released its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.09). The business had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million. On average, research analysts forecast that Evolus will post -0.61 earnings per share for the current year.

Insider Buying and Selling at Evolus

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $7.15, for a total transaction of $75,353.85. Following the transaction, the insider owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP purchased a new position in Evolus during the fourth quarter worth $545,000. Alpine Global Management LLC bought a new position in Evolus during the fourth quarter valued at $173,000. Virtu Financial LLC purchased a new stake in shares of Evolus in the fourth quarter valued at $151,000. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Evolus in the fourth quarter valued at $144,000. Finally, Wellington Management Group LLP lifted its holdings in shares of Evolus by 5.9% in the 4th quarter. Wellington Management Group LLP now owns 195,160 shares of the company’s stock worth $1,298,000 after acquiring an additional 10,850 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.